Abstract
The authors are developing an online resource to assist with smoking cessation advice. It is available at
References
Hawkins BT, Abbruscato TJ, Egleton RD, Brown RC, Huber JD, Campos CR, Davis TP. Nicotine increases in vivo blood–brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res. 2004; 1027:48-58
Carpenter CM, Wayne GF, Connolly GN. The role of sensory perception in the development and targeting of tobacco products. Addiction. 2007; 102:136-147
Brandon TH. Negative affect as motivation to smoke. Curr Direct Psychol Sci. 1994; 3:33-37
Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983; 51:390-395
Prochaska JO, Norcross JC, DiClemente CC. Applying the stages of change. Psychother Aust. 2013; 19
Orleans CT, Schoenbach VJ, Wagner EH, Quade D, Salmon MA, Pearson DC, Fiedler J, Porter CQ, Kaplan BH. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counselling. J Consult Clin Psychol. 1991; 59:439-448
Ferguson SG, Frandsen M, Dunbar MS, Shiffman S. Gender and stimulus control of smoking behavior. Nicot Tob Res. 2015; 17:431-437
Venters MH, Solberg LI, Kottke TE, Brekke M, Pechacek TF, Grimm RH Smoking patterns among social contacts of smokers, ex-smokers, and never smokers: the Doctors Helping Smokers Study. Prev Med. 1987; 16:626-635
Bandura A. Self-efficacy mechanism in human agency. Am Psychol. 1982; 37:122-147
Chaiton M, Diemert L, Cohen JE, Bondy SJ, Selby P, Philipneri A, Schwartz R. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open. 2016; 6
Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005; (2)
Fiore MC, Jaén CR, Baker TB Treating Tobacco Use and Dependence: 2008 Update.Rockville, MD: US Department of Health and Human Services. Public Health Service; 2008
Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2005; (2)
Stead LF, Perera T, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2006; (3)
Hoeppner BB, Hoeppner SS, Seaboyer L, Schick MR, Wu GW, Bergman BG, Kelly JF. How smart are smartphone apps for smoking cessation? A content analysis. Nicot Tob Res. 2016; 18:1025-1031
Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev. 2016; (4)
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86:1119-1127
Clinical Guidelines and Procedures for the Management of Nicotine Dependent Inpatients.Perth: Smoke Free WA Health Working Party, Health Networks Branch, Department of Health, Western Australia; 2011
Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012; 11
Henningfield JE, Radzius A, Cone EJ. Estimation of available nicotine content of six smokeless tobacco products. Tob Control. 1995; 4:57-61
Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. J Am Med Assoc. 1992; 268:2687-2694
Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, Wiseman D. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction. 1995; 90:31-42
Stapleton JA, Sutherland G. Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. Addiction. 2011; 106:824-832
Steinberg MB, Zimmermann MH, Delnevo CD, Lewis MJ, Shukla P, Coups EJ, Foulds J. E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices. J Gen Int Med. 2014; 29:1444-1450
Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler. Clin Pharmacokin. 2001; 40:661-684
Report on the scientific basis of tobacco product regulation: third report of a WHO study group.Geneva: WHO; 2009
Stanley TD, Massey S. Evidence of nicotine replacement's effectiveness dissolves when meta-regression accommodates multiple sources of bias. J Clin Epidemiol. 2016; 79:41-45
Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013; 170:1460-1467
Cahill K, Stead LF, Lancaster T, Polonio IB. Nicotine receptor partial agonists for smoking cessation. Sao Paulo Med J. 2012; 130:346-347
Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015; 15
Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. J Am Med Assoc. 2006; 296:64-71
Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. Br Med J. 2015; 350
Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chronic Obstruct Pulmon Dis. 2008; 3:45-53
Warner C, Shoaib M. How does bupropion work as a smoking cessation aid?. Addiction Biol. 2005; 10:219-231
Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med. 2008; 121:20-31
Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol. 2003; 59:767-773
GlaxoSmithKline Zyban (bupropion hydrochloride) Sustained Release Tablets. Product Information. 2017. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Zyban/pdf/ZYBAN-PI-MG.PDF (Accessed 29 March 2018)
Gonzales D, Rennard SI, Nides M Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. J Am Med Assoc. 2006; 296:47-55
Corelli RL, Hudmon KS. Medications for smoking cessation. West J Med. 2002; 176:131-135
Hughes JR. Motivating and helping smokers to stop smoking. J Gen Int Med. 2003; 18:1053-1057
Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicot Tob Res. 2013; 15:267-270
Yamin CK, Bitton A, Bates DW. E-cigarettes: a rapidly growing Internet phenomenon. Ann Intern Med. 2010; 153:607-609
Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial. The Lancet. 2013; 382:(9905)1629-1637
Hartmann-Boyce J, McRobbie H, Bullen C, Begh R, Stead LF, Hajek P. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2016; (9)
Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011; 106:2017-2028
Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control: a step forward or a repeat of past mistakes?. J Pub Health. 2011; 32:16-31
Borland R, Partos TR, Yong HH, Cummings KM, Hyland A. How much unsuccessful quitting activity is going on among adult smokers? Data from the International Tobacco Control 4-Country cohort survey. Addiction. 2012; 107:673-682
Kotz D, Brown J, West R. Predictive validity of the Motivation To Stop Scale (MTSS): a single-item measure of motivation to stop smoking. Drug Alcohol Depend. 2013; 128:15-19
Wiltshire S, Bancroft A, Parry O, Amos A. ‘I came back here and started smoking again’: perceptions and experiences of quitting among disadvantaged smokers. Health Educ Res. 2003; 18:292-303
Solberg LI, Boyle RG, Davidson G, Magnan SJ, Carlson CL. Patient satisfaction and discussion of smoking cessation during clinical visits. Mayo Clin Proc. 2001; 76:138-143
The dentist's role in smoking cessation management – a literature review and recommendations: part 2
Ross M Keat
Jean-Christophe Fricain
Sylvain Catros
Luis Monteiro
Luis Martins da Silva
Marcio Diniz Freitas
Angel Brandariz
Giovanni Lodi
Alberto Pispero
Saman Warnakulasuriya
Zahid Khan
Rui Albuquerque
From Volume 45, Issue 4, April 2018 | Pages 298-309
Article
During the second part of this article the ‘Transtheoretical Model’ of smoking cessation is discussed, which allows an understanding of the ‘stage’ of smoking or cessation patients currently occupy. Dental professionals can then tailor their brief advice to patients' individual needs.
Most tobacco users continue their use because they are addicted to nicotine. By smoking, long-term users modify their brain chemistry, meaning that it can be very difficult for individuals to stop.1 This can be replaced with ‘clean nicotine’ via nicotine replacement therapy (NRT), or the pleasurable effects of nicotine can be removed through utilization of pharmacotherapies.
Although nicotine plays a large part in an individual smoking, the process is undoubtedly multi-factorial. Pharmacology, genetics, learned habits and social/environmental factors all play their part.2 By smoking, users feel they can regulate their mood alongside their mental and physical abilities.3 Stop smoking services attempt to address these barriers during an individual's smoking cessation attempt.
Register now to continue reading
Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:
What's included
- Up to 2 free articles per month
- New content available